# Monocyte Activation in People With HIV and Tuberculosis Coinfection and Effect of Tuberculosis Preventive Therapy: An Analysis of the ACTG A5279/BRIEF TB Trial

**Authors:** Moises A Huaman, Manuel G Feria, Michelle A Kendall, Ashley McKhann, Khuanchai Supparatpinyo, Claire A Chougnet, Xinyu Du, Frederick K Sawe, Kristine M Erlandson, Netanya S Utay, Michael M Lederman, Susan Swindells, Amita Gupta, Richard E Chaisson, Carl J Fichtenbaum

PMC · DOI: 10.1093/ofid/ofaf771 · Open Forum Infectious Diseases · 2025-12-15

## TL;DR

This study shows that people with HIV and TB exposure have higher monocyte activation, and a shorter TB preventive therapy (1HP) reduces inflammation more effectively than a longer therapy (9H).

## Contribution

The study reveals that 1HP TPT reduces monocyte-driven inflammation more effectively than 9H in HIV-positive individuals with TB exposure.

## Key findings

- TST/IGRA-positive participants had ~2-fold higher monocyte activation markers compared to TST/IGRA-negative participants.
- 1HP TPT was associated with reduced CCR2+ monocyte percentages and blunted IL-6/TNF-α responses compared to 9H.
- Monocyte activation remained elevated in TST/IGRA-positive individuals both before and after TPT.

## Abstract

Monocyte activation contributes to the pathogenesis of inflammation-driven comorbidities in people with HIV (PWH). We investigated the impact of tuberculin skin test (TST)/interferon-γ release assay (IGRA) status and tuberculosis preventive therapy (TPT) on monocyte activation in PWH.

We analyzed peripheral blood mononuclear cells from participants from the A5279/BRIEF-TB trial, which compared 1 month of rifapentine/isoniazid (1HP) versus 9 months of isoniazid (9H) as TPT in PWH. All included participants were on suppressive antiretroviral therapy and had available TST or IGRA results at study entry. Samples collected at week 0 (pre-TPT) and week 48 (post-TPT) were analyzed. Monocyte subset and activation markers were measured using multiparameter flow cytometry. Proinflammatory cytokines (IL-6 and TNF-α) were assessed after 6-hour lipopolysaccharide (LPS) stimulation. Linear regression models were used for primary comparisons of monocyte markers by TST/IGRA status, adjusted for age, sex, country, and CD4 count.

In adjusted models, compared with TST/IGRA-negative participants (n = 27), TST/IGRA-positive participants (n = 30) had ∼2-fold relative increases in the median fluorescence intensity of CD64 (unstimulated) and CCR2 (post-LPS) on total monocytes and across monocyte subsets, pre- and post-TPT. Among TST/IGRA-positive participants, 1HP was associated with decreased fold changes over time for the percentage of CCR2+ monocytes and blunted IL-6/TNF-α responses compared with 9H.

PWH with a positive TST or IGRA exhibited signals of monocyte activation pre- and post-TPT. TPT with 1HP led to blunted proinflammatory monocyte changes compared with 9H.

## Linked entities

- **Proteins:** FCGR1A (Fc gamma receptor Ia), CCR2 (C-C motif chemokine receptor 2), IL6 (interleukin 6), TNF (tumor necrosis factor), IRF6 (interferon regulatory factor 6)
- **Chemicals:** rifapentine (PubChem CID 135403821), isoniazid (PubChem CID 3767)
- **Diseases:** tuberculosis (MONDO:0018076)

## Full-text entities

- **Genes:** IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CCR2 (C-C motif chemokine receptor 2) [NCBI Gene 729230] {aka CC-CKR-2, CCR-2, CCR2A, CCR2B, CD192, CKR2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, FCGR1A (Fc gamma receptor Ia) [NCBI Gene 2209] {aka CD64, CD64A, FCG1, FCGR1, FCRI, FcgammaRI}
- **Diseases:** TB (MESH:D014390), Proinflammatory cytokines (MESH:D000080424), inflammation (MESH:D007249), HIV and Tuberculosis Coinfection (MESH:D015658), Tuberculosis (MESH:D014376)
- **Chemicals:** isoniazid (MESH:D007538), LPS (MESH:D008070), rifapentine (MESH:C018421), 1HP (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12757864/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12757864/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12757864/full.md

---
Source: https://tomesphere.com/paper/PMC12757864